Evidence map›Paper›PMID 29688273›Full record

ReviewBriefings in bioinformatics2019

Community-driven roadmap for integrated disease maps.

Marek Ostaszewski, Stephan Gebel, Inna Kuperstein, Alexander Mazein, Andrei Zinovyev, Ugur Dogrusoz, Jan Hasenauer, Ronan M T Fleming, Nicolas Le Novère, Piotr Gawron and 8 more

Abstract readReview
In one paragraph

Review in Briefings in bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Review
  2. Article
  3. momapy: a Python library to work with molecular maps.Bioinformatics (Oxford, England) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Marek OstaszewskiLuxembourg Centre for Systems Biomedicine, Universite du Luxembourg, 7 Avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.
Stephan GebelLuxembourg Centre for Systems Biomedicine, Universite du Luxembourg, 7 Avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.
Inna KupersteinInstitut Curie, PSL Research University, INSERM U900, F-75005 Paris, France and CBIO-Centre for Computational Biology, MINES ParisTech, PSL Research University, F-75006 Paris, France.
Alexander MazeinEuropean Institute for Systems Biology and Medicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM, Université de Lyon, 50 Avenue Tony Garnier, 69007 Lyon, France.
Andrei ZinovyevInstitut Curie, PSL Research University, INSERM U900, F-75005 Paris, France and CBIO-Centre for Computational Biology, MINES ParisTech, PSL Research University, F-75006 Paris, France.
Ugur DogrusozComputer Engineering Department, Faculty of Engineering, Bilkent University, Ankara 06800, Turkey.
Jan HasenauerInstitute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
Ronan M T FlemingDivision of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, Leiden, Netherlands.
Nicolas Le NovèreThe Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom.
Piotr GawronLuxembourg Centre for Systems Biomedicine, Universite du Luxembourg, 7 Avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.
Thomas LigonFaculty of Physics and Center for NanoScience (CeNS), Ludwig-Maximilians-Universität, 80539 München, Germany.
Anna NiarakisGenHotel EA3886, Univ Evry, Université Paris-Saclay, Evry 91025, France.
David NickersonAuckland Bioengineering Institute, University of Auckland, Auckland, New Zealand.
Daniel WeindlInstitute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany.
Rudi BallingLuxembourg Centre for Systems Biomedicine, Universite du Luxembourg, 7 Avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.
Emmanuel BarillotInstitut Curie, PSL Research University, INSERM U900, F-75005 Paris, France and CBIO-Centre for Computational Biology, MINES ParisTech, PSL Research University, F-75006 Paris, France.
Charles AuffrayEuropean Institute for Systems Biology and Medicine, CIRI UMR5308, CNRS-ENS-UCBL-INSERM, Université de Lyon, 50 Avenue Tony Garnier, 69007 Lyon, France.
Reinhard SchneiderLuxembourg Centre for Systems Biomedicine, Universite du Luxembourg, 7 Avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Disease Maps Project builds on a network of scientific and clinical groups that exchange best practices, share information and develop systems biomedicine tools. The project aims for an integrated, highly curated and user-friendly platform for disease-related knowledge. The primary focus of disease maps is on interconnected signaling, metabolic and gene regulatory network pathways represented in standard formats. The involvement of domain experts ensures that the key disease hallmarks are covered and relevant, up-to-date knowledge is adequately represented. Expert-curated and computer readable, disease maps may serve as a compendium of knowledge, allow for data-supported hypothesis generation or serve as a scaffold for the generation of predictive mathematical models. This article summarizes the 2nd Disease Maps Community meeting, highlighting its important topics and outcomes. We outline milestones on the roadmap for the future development of disease maps, including creating and maintaining standardized disease maps; sharing parts of maps that encode common human disease mechanisms; providing technical solutions for complexity management of maps; and Web tools for in-depth exploration of such maps. A dedicated discussion was focused on mathematical modeling approaches, as one of the main goals of disease map development is the generation of mathematically interpretable representations to predict disease comorbidity or drug response and to suggest drug repositioning, altogether supporting clinical decisions.

Indexed as

Gene Regulatory NetworksGenetic Predisposition to DiseaseComputational BiologyHumansModels, StatisticalTranslational Research, Biomedicalbiocurationdisease mapsknowledge repositorymathematical modelingmolecular biologypathway representationtranslational medicine

Identifiers

PMID29688273
PMCPMC6556900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.